Pfizer CEO Albert Bourla (AP Images)
Pfizer can restart PhIII trial of Duchenne gene therapy, now on track for late-2023 FDA approval request
Pfizer’s path at getting a gene therapy to market for patients with Duchenne muscular dystrophy just got a little clearer after a hazy 2021 that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
